Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 in Advanced Solid Tumors and mCRC
NCT01117428Phase 2Completed
- Sponsor
- Symphogen
- Start
- Mar 2010
- Primary completion
- Feb 2015
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of futuximab + modotuximab in solid tumor, metastatic colorectal cancer (mCRC), sponsored by Symphogen. Started Mar 2010; status: completed.
02
Drugs
futuximab + modotuximab
03
Conditions
solid tumormetastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01117428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117428.